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Supplement Aims and Scope
Cancer Informatics represents a hybrid discipline encompassing the fields of oncology, computer science, bioinformatics, statistics, computational biology, genomics, proteomics,
metabolomics, pharmacology, and quantitative epidemiology.
The common bond or challenge that unifies the various disciplines is the need to bring order to the massive amounts of
data generated by researchers and clinicians attempting to find
the underlying causes and effective means of treating cancer.
The future cancer informatician will need to be well-versed
in each of these fields and have the appropriate background
to leverage the computational, clinical, and basic science
resources necessary to understand their data and separate
signal from noise. Knowledge of and the communication
among these specialty disciplines, acting in unison, will be
the key to success as we strive to find answers underlying the
complex and often puzzling diseases known as cancer.
Articles focus on computer simulation, bioinformatics,
and statistical analysis of cancer data and processes and
may include:
Multi-dimensional Simulation Models of Tumour
Response
Simulating Tumour Growth Dynamics

Spatio-Temporal Simulation Models
Parametric Validation of Simulation Models
Simulation of Dynamic Phenomena in Cancer using
Highly Specialized Algorithms
Hyper-High Performance and Biocomplexity Systems
Modelling of Cancer
Sequence Alignment Methods for DNA-Seq, RNASeq, miRNA-Seq, CHiP-Seq Experiments
Spectra Analysis
Generic Visualization Tools
Array-Comparative Genomic Hybridization
Visualization
Statistical Methods for Next Generation Sequencing
Data
Predictive Modeling for High-Dimensional Data
Robust Feature Selection
Integration and Analysis of Big Biomedical Data
Meta-Data Imaging
Equivalent Cross-Relaxation Imaging
Mathematical Modeling and Image Enhancement of
MRI Cancer Data
Rapid Imaging Analysis of PET Cancer Scans
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ancer is a widely-recognized public health burden and a
complex disease. High-dimensional “Omics” research
– research that uses high dimensional genomic, proteomic, and/or metabolomic data – has often been motivated
by cancer applications1. Important lessons have been learned
in processing and analyzing such data. Further, additional
sophisticated technologies in medical imaging, geographic
information systems, and environmental exposure monitoring also give rise to high-dimensional data. Yet, as quickly as
methods adapt to the new technologies, it seems that biotechnological developments produce even higher dimensional and
more complex datasets – making bioinformatics more and
more critical to the processing and understanding of patient
data. But, in the rush of data processing we must not lose
sight of biostatistics principles so that data are correctly interpreted, signal separated from noise, and new discoveries efficiently translated into clinical practice without unnecessary
delays or inefficiencies. This supplement includes articles by
various researchers in statistics, biostatistics and bioinformatics who are developing methods for addressing a wide spectrum of scientific questions related to big data. Some of these
main areas are summarized below.
As mentioned, the challenges facing today in cancer
informatics are multifaceted lying at the interface of bioinformatics, genetic epidemiology, epigenetics, and risk prediction,
and several authors contributed in these areas. In particular,
some papers focused on the approaches for detecting gene-gene
and gene-environment interactions. Talluri and Shete considered an information theory approach for detecting epistasis,
compared it with a standard logistic regression approach, and
demonstrated utility by applying it to head and neck cancer
data. Liu and Xuan constructed a mutual SNP association
network (SAN) based on information from various sources of
gene interaction such as protein-protein interaction and gene
co-expression, with the goal that SAN reflects the real functional associations between genomic loci. Zhang and Biswas
focused on detecting interactions of rare haplotypes with environmental covariates with an enhanced version of Logistic
Bayesian LASSO and used it to uncover a rare haplotype
interaction with smoking for lung cancer. Zang et al. conside
red lung cancer and explored the association of its sub-types
with CDKN3 gene expression, and found that higher expression of CDKN3 was associated with poorer survival outcomes
for lung adenocarcinoma but not for squamous cell carcinoma.
Sun and Li developed a pipeline to identify hemi-methylation,
that is, DNA methylation occurring in one strand only, and
characterized different patterns in the entire genome, and
applied the method to breast cancer cell lines. Mazzola et al.
reviewed many recent enhanced capabilities of the widely used
breast cancer genetic risk prediction model BRCAPRO that
estimates the probability that a counselee carries mutations of
BRCA1 or BRCA2 genes given her family history.
Other papers focused on extensions and applications
of penalized or regularized models, such as the LASSO.
248
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Zemmour et al. took an important look back at centrally
important breast cancer datasets. These datasets had previously been used to develop bioinformatic diagnostic tools that
are currently in use. But these tools were developed when we
knew less about the statistics of this type of data than we do
today. They applied regularized methods that are becoming the
gold standard in this area. They found that shorter and arguably more robust gene lists with equivalent prediction value
are the result. They also found that the overlap of the gene
lists from different modern tools is much higher than with the
previous tools, suggesting that the previous poor overlap may
have caused unnecessary concerns. Other articles pertained to
extending penalized methods for discrete response modeling.
For example, ordinal responses have an inherent ordering, but
the distance between the responses cannot be quantitatively
measured. Examples of ordinal variables include tumor grade
(T0 to T4), degree of spread to the lymph nodes (N0 to N3),
and cancer stage (I to IV), all of which are commonly reported
in cancer research studies. The ordinal generalized monotone
incremental forward stagewise method (GMIFS) was previously described for fitting ordinal response models in the presence of a high-dimensional covariate space. Ferber and Archer
demonstrated how the GMIFS algorithm, via a forward continuation ratio model, could be used to fit a discrete survival
time response model, applicable when survival is recorded on
an ordinal scale such as short-, intermediate-, and long-term
survival. Gentry et al extended the ordinal GMIFS algorithm
to enable inclusion of covariates that should not be penalized
in the model fitting process, and applied the method to predict
stage of breast cancer using methylation of high-throughput
CpG sites as penalized predictors with important clinical
covariates coerced into the model. Makowski and Archer
extended the GMIFS method to the Poisson regression setting
for modeling a count response in high-dimensional covariate
spaces, and applied the method for predicting micronuclei frequency using gene expression features as predictors.
In order to understand the gene regulatory mechanism
in cancer, Wei P et al. proposed a novel statistical framework
to integrate diverse types of genomic data from The Cancer
Genome Atlas (TCGA) to decipher expression regulation.
Wei Y et al. tackled a similar problem and proposed joint
models for integrative analysis of multiple types of omics data.
The results from the analysis shed light on personalized medicine. Statistical methods for differential expression analysis
in both microarray and RNA-seq have been well-developed,
however, the method for equivalent expression analysis is
still seriously lacking. Cui et al. proposed a novel statistical
method to test equivalent expressions among multiple treatment groups. Zhou et al. compared the traditional approach
of univariate modeling to linear mixed effects modeling when
assessing the relationship between psychoneurological symptoms (anxiety, depression, and stress) and methylation of CpG
sites. O’Donnell et al. examined the exciting and emerging
area of immunology signatures in cancer. Their goal was to
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investigate the potential for development of an early detection and diagnostic tool that can be used on a simple blood
draw. Their intriguing approach uses a peptide microarray and
a time-frequency analysis. Zhao et al. reported on the develo
pment of informatics for a precision oncology – personalized medicine – clinical trial. The molecular profiling-based
assignment of cancer therapy trial (MPACT) uses genomic
profiling in novel ways to determine patient treatment. It is
one of the first in what is likely to be a long line of such trials,
and they describe how complex molecular characterization
of the patients can be folded into clinical trial randomization
and quality control. They show that careful development of
bioinformatics tools can facilitate optimal interactions among
diverse multidisciplinary teams composed of clinicians,
molecular oncologists, statisticians and bioinformaticians.
Some articles pertained to analyzing the spatial dimension in cancer. A catchment area is the geographic area and
population from which a cancer center draws patients, and
defining a catchment area allows a cancer center to describe
its primary patient population and assess how well it meets
the needs of cancer patients. Wang and Wheeler estimated
diagnosis and treatment catchment areas for the Massey Cancer Center at Virginia Commonwealth University using cancer registry and patient billing data and Bayesian hierarchical
regression models. Historically, generalized additive models
with bivariate smoothing functions have been applied to estimate spatial variation in cancer risk. Siangphoe and Wheeler
evaluated the ability of different smoothing functions in genera
lized additive models to detect overall spatial variation of risk
and elevated risk in diverse geographical areas using a simulation study.
Another aspect of spatial dimension in cancer is the heterogeneity within each tumor, especially in regard to changes
over time. Diffusion tensor imaging provides a way to image
brain tumors. To assess changes over time from treatment and
tumor growth, it is necessary to register serial images against
a high-quality reference of pure brain tissue. This allows
comprehensive visualization of the entire tumor progression
through the course of treatment. Ceschin et al provide an open
source pipeline, sfDM (serial functional diffusion mapping),
for registering and processing the images. They also evaluate different registration methods. Hobbs and Ng are concerned with monitoring tumor characteristics via perfusion
imaging, and describe a model-based approach for inferring
stability for stochastic curve estimation, a useful statisticallybased technique.

Other articles described methods for assessing environmental chemical exposures. Environmental variables used in
regression models to explain environmental chemical exposures or cancer outcomes are typically modeled at the same
spatial scale. Grant, Gennings, and Wheeler presented four
model selection algorithms that select the best spatial scale
for each area-based covariate to explain variation in groundwater nitrate concentrations in Iowa. In the evaluation of
cancer risk related to environmental chemical exposures, the
effect of many chemicals on disease is ultimately of interest.
The method of weighted quantile sum (WQS) regression
attempts to overcome these problems by estimating a body
burden index that identifies important chemicals in a mixture
of correlated environmental chemicals. Czarnota, Gennings,
and Wheeler assessed through simulation studies the accuracy
of WQS regression in detecting subsets of chemicals associated with health outcomes and found that WQS regression
had good sensitivity and specificity across a variety of conditions. The relationship between correlated environmental
chemicals and health effects was not always constant across a
study area, as exposure levels may change spatially due to various environmental factors. Czarnota, Wheeler, and Gennings
assess through a simulation study the ability of geographically
weighted regression (GWR) and geographically weighted
lasso (GWL) to correctly identify spatially varying chemical
effects for a mixture of correlated chemicals within a study
area and find that GWR suffered from the reversal paradox,
while GWL over-penalized the effects for the chemical most
strongly related to the outcome.
A promising approach to cancer treatment leverages new
understanding of the role of cancer stem cells (CSCs) and discovery of agents targeting them. Day uses tumor dynamics
modeling to illustrate two special challenges in CSC-targeted
treatment: how to design combination regimens that stand the
best chance of success, and how to design clinical trials with
time frames and endpoints sufficient to detect highly successful regimens that otherwise would be missed.
Reference
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Director of the Massey Cancer Center Biostatistics Shared Resource at
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such as those arising from high-throughput genomic platforms. Dr. Archer is
the author or co-author of 99 published papers, two book chapters, has 30
university seminars/professional conference presentations, holds an editorial
appointment at Progress in Transplantation and is a Statistical Consultant for
Radiology and the Nature Publishing Group.
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years. His current research focuses primarily on evaluating identifier mapping

http://www.pittsburghartistregistry.org/accounts/
view/RogerDayPanEthnicTuba

and filtering methods for high-throughput proteomics and expression platforms,
promoting innovative and ethical design and execution of clinical trials, software
architecture for comprehensive cancer modeling and validation, multi-scale
modeling in cancer, strategies for overcoming drug resistance in cancer, and novel
approaches to modeling pharmaceutical and biological interactions. Dr. Day is the
author or co-author of 80 published peer-reviewed or proceedings papers. He is
a devoted teacher and mentor, and highly active musician.

250

CANCER INFORMATICS 2015:14(S2)

Cancer Informatics
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such as microarrays and second-generation sequencing. He collaborates closely
with researchers working on epigenetics to characterize different types of DNA
methylation and histone modifications. Dr. Wu is the author or co-author of 37
published papers in peer-reviewed journals, two book chapters, and has over 30
invited seminars at different academic institutes and professional conferences.
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